Marinus Pharmaceuticals Inc (STU:61Y)
€ 1.61 0.12 (8.05%) Market Cap: 88.85 Mil Enterprise Value: 82.45 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 36/100

Q3 2020 Marinus Pharmaceuticals Inc Earnings Call Transcript

Nov 09, 2020 / 09:30PM GMT
Release Date Price: €11.06 (-2.66%)
Operator

Greetings and welcome to the Marinus Pharmaceuticals Third Quarter 2020 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.

And it's now my pleasure to introduce your host, Sasha Damouni Ellis, Vice President, Investor Relations and Corporate Communications. You may begin, Ms. Damouni Ellis.

Sasha Damouni Ellis
Marinus Pharmaceuticals, Inc. - VP of IR & Corporate Communication

Thank you, and good afternoon, everyone. With me from Marinus are Dr. Scott Braunstein, Chief Executive Officer; Dr. Joe Hulihan, Chief Medical Officer; and Edward Smith, Chief Financial Officer.

Before we begin, I would like to remind everyone that some of the statements made today could be termed as forward looking under the securities laws. These forward-looking statements, of course, are subject to certain risks and uncertainties that are associated with our business and that could cause our future results to differ significantly from those expressed or implied by the forward-looking statements. For a description of these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot